

Special Issue

New Advances in Antibiotic Therapy in the Gastroenterology Field

Message from the Guest Editors

Antibiotic therapy plays a pivotal role in managing gastrointestinal (GI) infections, liver diseases, and microbiota-associated disorders. However, the rise of antimicrobial resistance, evolving gut microbiome research, and novel therapeutic approaches are reshaping the landscape of antibiotic use in gastroenterology. This Special Issue explores cutting-edge advancements, including targeted antibiotic strategies, microbiome-sparing therapies, and precision medicine approaches for GI infections and liver diseases. Additionally, we highlight the implications of gut dysbiosis, antimicrobial stewardship, and emerging alternatives such as bacteriophage therapy and microbiota-based interventions. By integrating microbiology, pharmacology, and clinical practice, this collection aims to provide insights into optimizing antibiotic use while mitigating resistance and preserving gut health. We invite contributions from researchers and clinicians to advance our understanding of the evolving role of antibiotics in gastroenterology and hepatology, paving the way for more effective and sustainable therapeutic strategies in this rapidly developing field.

Guest Editors

Dr. Giuseppe Guido Maria Scarlata

Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy

Dr. Francesca Serapide

Department of Medical and Surgical Sciences, University "Magna Graecia", 88100 Catanzaro, Italy

Deadline for manuscript submissions

28 February 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/236825

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)